

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO**

ELI LILLY AND COMPANY,

Plaintiff,

v.

ED PARTNERS, LLC D/B/A
CLEVELAND HEALTH GROUP,

Defendant.

Case No. 1:24-cv-1035

JURY TRIAL DEMANDED

**COMPLAINT FOR TRADEMARK INFRINGEMENT,
FALSE ADVERTISING, FALSE DESIGNATION OF ORIGIN,
AND DECEPTIVE TRADE PRACTICES**

INTRODUCTION

1. This is an action to protect patients from unstudied, unapproved, and unsafe drugs masquerading as Plaintiff Eli Lilly and Company's ("Lilly") FDA-approved medicines for adults with type 2 diabetes, obesity, or excess weight and weight-related medical problems. Defendant Ed Partners LLC d/b/a Cleveland Health Group ("Defendant") has designed its website, social media, and advertising materials to deceive patients into thinking Defendant offers a way to obtain Lilly's clinically studied medicines, when in reality Defendant offers no such thing.¹ Lilly therefore brings this action under federal and state law to protect patients from Defendant's dangerous, deceptive, and unlawful practices.

2. For nearly 150 years, Lilly has worked tirelessly to develop and deliver trusted and innovative medicines that meet critical and unmet patient needs. Lilly's proprietary MOUNJARO[®] and ZEPBOUND[®] are two such first-of-their-kind medicines, which are indicated for the serious conditions afflicting many tens of millions of Americans. To advance treatment of these chronic conditions, Lilly used its extensive experience with world-class medicines to develop the brand-new class of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulintropic polypeptide) dual-receptor agonists, which includes tirzepatide, the active ingredient in Lilly's MOUNJARO[®] and ZEPBOUND[®]. Lilly's MOUNJARO[®] and ZEPBOUND[®] are the only FDA-approved GLP-1/GIP medicines.

3. Before obtaining FDA approval, Lilly's new medicines underwent years-long clinical trials, which tested them for safety, quality, and effectiveness on thousands of patients. When approving these medicines, the FDA called Lilly's "novel" MOUNJARO[®] an "important


¹ In support of this Complaint, Lilly's allegations are upon actual knowledge with respect to itself and its own acts, and upon information and belief as to all other matters.

advance” and observed that Lilly’s ZEPBOUND® “addresses an unmet medical need.” <https://web.archive.org/web/20221028212253/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes> (archived FDA MOUNJARO® approval press announcement); <https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management> (FDA ZEPBOUND® approval press announcement).

4. Compounded products sold as “tirzepatide,” meanwhile, are not approved or even reviewed by the FDA. Pharmacies currently offering compounded versions of tirzepatide are not required to follow the FDA’s “good manufacturing practices,” nor to comply with the same controls on sterility and safe storage as manufacturers of FDA-approved medicines. They are also not required to report adverse events—an important regulatory requirement imposed on manufacturers of FDA-approved medicines for patient safety. Compounded drugs are not tested for safety, quality, or efficacy in clinical trials. Accordingly, and as the FDA has warned, “compounded drugs pose a higher risk to patients than FDA-approved drugs,” such as MOUNJARO® and ZEPBOUND®. <https://www.fda.gov/drugs/human-drug-compounding/drug-compounding-and-drug-shortages> (FDA explainer on Drug Compounding).

5. Defendant falsely and unlawfully trades on Lilly’s work, reputation, and goodwill, offering unproven and unapproved compounded drugs as if they were genuine Lilly medicines or generic versions thereof. But Defendant does not offer Lilly’s proprietary MOUNJARO® and ZEPBOUND® medicines, nor any FDA-approved “generic” version of them. Indeed, Defendant’s drugs have undergone *none* of the rigorous studies or approval processes that Lilly’s medicines have. Passing Defendant’s compounded drugs off as Lilly’s MOUNJARO® and ZEPBOUND® is not merely deceptive—it’s dangerous.

6. Defendant's intentional deception is evident from its social media accounts, where in dozens of posts Defendant advertises by unnecessarily invoking the MOUNJARO[®] Mark and falsely claiming that its tirzepatide product is "FDA approved" or backed by research, as shown below.



7. Defendant also uses its website to falsely advertise its products. For example, in a video posted to Defendant's tirzepatide webpage, Defendant refers to its product at timestamp 0:09 as "generic MOUNJARO[®]."

8. Despite these repeated and impossible-to-miss advertisements, Defendant's products are not "FDA approved," are not the same tirzepatide as is used in MOUNJARO[®], and are not "shown" to have any effects. Nor can it be "generic MOUNJARO[®]," because there is *no such thing* as "generic MOUNJARO[®]." Rather, Defendant's products are unstudied, unapproved, and unsafe.

9. Lilly therefore brings this action pursuant to the Lanham Act, 15 U.S.C. §§ 1051 *et seq.*, and for violation of Ohio statutory and common law regarding deceptive and unfair trade practices. Lilly's claims arise out of Defendant's infringement of Lilly's rights in the MOUNJARO[®] and ZEPBOUND[®] trademarks and Defendant's acts of false designation of origin, false advertising, and deceptive trade practices.

THE PARTIES

10. Plaintiff Lilly is a corporation organized and existing under the laws of Indiana and has its principal place of business in Indiana.

11. Defendant is an Ohio limited liability company d/b/a Cleveland Health Group, with a principal place of business at 6571 Brecksville Road, Independence, Ohio 44131 in this District. Its registered agent is Registered Agents Inc. with a registered agent address 6545 Market Avenue N, Suite 100, North Canton, Ohio, 44721.

12. Defendant also does business using the domain name “<https://clevelandhealthgroup.com/>.”

JURISDICTION AND VENUE

13. The Court has subject matter jurisdiction over the Lanham Act causes of action pleaded herein pursuant to 15 U.S.C. § 1121 and 28 U.S.C. §§ 1331 and 1338(a). The Court has supplemental jurisdiction over the state and common law causes of action pleaded herein pursuant to 28 U.S.C. §§ 1338(b) and 1367(a).

14. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendant operates and conducts business in this District. Defendant is subject to personal jurisdiction in this District.

**LILLY’S FDA-APPROVED TIRZEPATIDE MEDICINES:
MOUNJARO® AND ZEPBOUND®**

15. Lilly’s MOUNJARO® is a novel treatment for type 2 diabetes, a chronic and progressive condition facing more than 30 million Americans. As the FDA has noted, “Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.”

<https://web.archive.org/web/20221028212253/https://www.fda.gov/news-events/press->

announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes (archived FDA MOUNJARO[®] approval press announcement). MOUNJARO[®] targets this problem head-on using an innovative active pharmaceutical ingredient, tirzepatide. Before it received FDA approval, Lilly's MOUNJARO[®] was clinically proven to improve blood sugar control "more effective[ly] than the other diabetes therapies with which it was compared in clinical studies."

Id.

16. The FDA approved MOUNJARO[®] and indicated it in addition to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As part of the approval process, Lilly submitted data on safety, quality, and effectiveness collected through clinical trials involving thousands of patients. Lilly's MOUNJARO[®] is thus proven safe and effective when used as directed.

17. In addition to MOUNJARO[®], Lilly markets and sells ZEPBOUND[®], another proprietary, FDA-approved treatment option containing the active pharmaceutical ingredient tirzepatide. With ZEPBOUND[®], Lilly aims to help the many dozens of millions of American adults with obesity or with excess weight and weight-related medical problems lower their risks of cardiovascular disease and other leading causes of death. As the FDA has noted, ZEPBOUND[®] "addresses an unmet medical need" by targeting "chronic weight management (weight reduction and maintenance)" through a new method of hormone receptor activation. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management> (FDA ZEPBOUND[®] approval press announcement).

18. As with MOUNJARO[®], the safety, quality, and effectiveness of ZEPBOUND[®] was established through rigorous clinical trials featuring thousands of patients. The FDA recently approved ZEPBOUND[®] and indicated it for adults with obesity (with a BMI of 30

kg/m² or greater) or those who are overweight (with a BMI \geq 27 kg/m² or greater) and also have at least one weight-related additional condition, such as hypertension (high blood pressure), dyslipidemia (high cholesterol or fats in blood), type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease, to lose weight. It should be used with a reduced-calorie diet and increased physical activity.

19. Lilly's tirzepatide medicines are the result of billions of dollars of investments in research and development, which included dozens of studies and trials.

20. Countless highly specialized personnel ensure Lilly medicines meet quality and safety standards. Lilly manufactures its medicines under strict controls in state-of-the-art facilities. Transforming tirzepatide API to medicine is a complex, methodical, and science-based process. Lilly follows Good Manufacturing Practices (GMP), which are regulations that "provide[] for systems that assure proper design, monitoring, and control of manufacturing processes and facilities." <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp> (FDA explainer on GMP). GMPs include "establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories." *Id.* GMPs help "prevent instances of contamination, mix-ups, deviations, failures, and errors." *Id.*

21. Each step in Lilly's process to manufacture its tirzepatide medicines—from sourcing and chemical synthesis of the API to formulation and device assembly and packaging—requires extensive testing and controls and specialized equipment. Lilly's medicines must be, and always are, accompanied with important, FDA-approved labels, instructions, and warnings.

22. Lilly now promotes, offers, and sells MOUNJARO[®] and ZEPBOUND[®] medicines in Ohio and throughout the United States.

LILLY’S MOUNJARO[®] AND ZEPBOUND[®] TRADEMARKS

23. Lilly uses the trademarks MOUNJARO[®] and ZEPBOUND[®] (the “Lilly Marks”) to identify and promote Lilly’s proprietary, FDA-approved medicines with the active pharmaceutical ingredient tirzepatide. Lilly markets and sells MOUNJARO[®] and ZEPBOUND[®] throughout the United States using the Lilly Marks.

24. Lilly first adopted and used the MOUNJARO[®] mark at least as early as June 3, 2022, and has used the MOUNJARO[®] mark continuously since that time. Lilly has extensively promoted, advertised, and marketed its prescription-only diabetes medicine bearing the MOUNJARO[®] mark in many different channels, directed both to healthcare professionals and to patients.

25. Lilly is the owner of two federal trademark registrations for MOUNJARO[®], U.S. Reg. Nos. 6,809,369 (issued August 2, 2022) and 7,068,463 (issued May 30, 2023). True and correct copies of Plaintiff Lilly’s registrations for the MOUNJARO[®] mark are attached hereto as part of **Exhibit A**. Lilly additionally has several pending applications to register its MOUNJARO[®] mark in connection with more classes, services, and goods, including U.S. Trademark Ser. Nos. 97/596,856, 97/668,206, and 98/253,743. As a result of its use of the MOUNJARO[®] mark, Lilly also owns valuable common law and other rights in and to the MOUNJARO[®] mark.

26. Lilly first adopted and used the ZEPBOUND[®] mark at least as early as November 30, 2023, and has used the ZEPBOUND[®] mark continuously since that time. Lilly has extensively promoted, advertised, and marketed its prescription-only weight-loss medicine

bearing the ZEPBOUND[®] mark in many different channels, directed both to healthcare professionals and to patients.

27. Lilly is the owner of one federal trademark registration for ZEPBOUND[®], U.S. Reg. No. 7,288,373 (issued January 23, 2024). A true and correct copy of Plaintiff Lilly's registration for the ZEPBOUND[®] mark is attached hereto as part of **Exhibit A**. Lilly additionally has several pending applications to register its ZEPBOUND[®] mark, including U.S. Trademark Ser. Nos. 97/530,451, 97/530,456, and 98/295,137. As a result of its use of the ZEPBOUND[®] mark, Lilly also owns valuable common law and other rights in and to the ZEPBOUND[®] mark.

28. Lilly conceived the Lilly Marks to stand out in the marketplace. The Lilly Marks do not describe any attributes of either medicine and are accordingly inherently distinctive.

29. Lilly promotes, advertises, and markets MOUNJARO[®] and ZEPBOUND[®] both to healthcare professionals and to patients, among others, through various channels, including on the websites mounjaro.com, mounjaro.lilly.com, zepbound.com, and zepbound.lilly.com, in social media, in online advertisements, and on television.

30. As a result of Lilly's use, promotion, advertising, and marketing of MOUNJARO[®] and ZEPBOUND[®], the Lilly Marks are exclusively associated with Lilly, serve to identify genuine Lilly products, and are valuable assets of Lilly.

THE RISKS OF COMPOUNDING

31. Upon information and belief, Defendant markets and sells to patients compounded drug products that purport to contain tirzepatide and that are not approved by the FDA or any other global regulatory agency ("Unapproved Compounded Drugs").

32. Typically, prescription medicines must undergo a rigorous premarket approval process. Federal law creates a narrow exception for compounding, which the FDA defines as a

“practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.”

<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding> (FDA guidance on drug compounding law compliance). This narrow exception applies, for instance, where a patient cannot safely take a commercially manufactured FDA-approved drug due to an allergy to a particular dye.

33. The Food, Drug, and Cosmetic Act (FDCA), in section 503A, prescribes a rigid set of requirements that compounding pharmacies must meet, including a requirement that compounding occur only “on the prescription order that a compounded product is necessary for the identified patient.” This restriction is important because compounding pharmacies are not required to comply with GMP, so they are only permitted to produce a small amount based on the specific needs of specific patients. The FDA has explained the importance of this requirement to ensure that compounding pharmacies “are not actually operating as conventional manufacturers”:

The longer a compounded sterile drug product that has been contaminated is held by a pharmacist or physician before distribution, or held in inventory in a health care facility before administration, the greater the likelihood of microbial proliferation and increased patient harm. Because of these and other risks, the FD&C Act places conditions on compounding that must be met for compounded drugs to qualify for the exemptions in section 503A, [including that] compounding is for an identified individual patient, drugs compounded in advance of receiving prescriptions are compounded only in limited quantities, and drugs are distributed pursuant to a valid patient-specific prescription. These conditions are meant to help ensure that compounding under section 503A is based on individual patient needs, and that entities purportedly operating under section 503A are not actually operating as conventional manufacturers.

<https://www.fda.gov/media/97347/download> (FDA prescription requirement compliance guidance for industry).

34. As FDA further explained, “The *prescription requirement* under section 503A is a critical mechanism to distinguish compounding by a licensed pharmacist or licensed physician from conventional manufacturing, and to ensure that drug products compounded under section 503A, which are not FDA-approved, are not subject to the requirement that labeling bear adequate directions for use, and are not subject to []GMP requirements, are provided to a patient only based on individual patient need.” *Id.* (emphasis in original).

35. Compounders are also limited in their ability to engage in a practice called anticipatory compounding, which is when, “based on a history of receiving prescriptions for a particular drug product to be compounded for an identified individual patient, and in the context of an established relationship with a particular prescriber or patient, a pharmacist or physician will compound a batch of drugs in anticipation of receiving another patient-specific prescription. The compounder then provides the drugs to a patient or health care provider when a prescription for an identified individual patient is received.” *Id.* As the FDA further explained:

[A]nticipatory compounding [] has risks. For example, if a problem occurs during compounding, such as contaminating a drug product that is supposed to be sterile, or producing subpotent or superpotent sterile or non-sterile drugs, it could affect numerous patients, and not just one. Because drug products compounded in accordance with section 503A are exempt from CGMP requirements, there is an inherently greater chance of a production mistake or contamination. Restricting anticipatory compounding to limited quantities serves to limit the number of patients likely to be affected if there are drug product mix-ups or contamination. The limitations on anticipatory compounding in section 503A (i.e., compounding must be in “limited quantities” and based on an “established relationship”) help to protect patients from product quality issues. ***These limitations on anticipatory compounding also help to distinguish licensed pharmacists or licensed physicians compounding drug products under section 503A for individual patients from conventional manufacturers, who generally produce larger quantities of drugs that are distributed without a prescription.***

Id. (emphasis added).

36. According to the FDA, “[c]ompounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before

they reach patients.” The FDA has warned that: “Compounded drugs . . . do not have the same safety, quality, and effectiveness assurances as approved drugs. Unnecessary use of compounded drugs unnecessarily exposes patients to potentially serious health risks. Because compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness, or quality before they are marketed.” <https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers> (FDA drug compounding FAQ).

37. Health risks from compounded drugs are serious. In 2021, a pharmacist pled guilty to providing adulterated compounded drugs to cataract surgery patients. The adulterated compounds contained “an excessive amount of an inactive ingredient” that can damage sensitive eye tissue. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/press-releases/texas-pharmacist-pleads-guilty-adulterating-drug-used-cataract-surgeries> (FDA press announcement re guilty plea). At least 68 patients were injected with the adulterated compounds, at two different surgery centers, over a period of months, even though patients suffered near-immediate adverse events, including permanent blindness.

<https://www.wfaa.com/article/news/do-not-publish-yet/287-5f002ed3-e110-4063-9959-a2e5f54b5097> (WFAA article re outbreak). One patient had believed “every pill you take, every shot you take is tested” and was surprised to learn that compounded drugs were neither fully tested nor deemed safe or otherwise approved by the FDA. *Id.*

38. There are countless other examples of people experiencing serious injury from taking unregulated medicines. Inappropriate drug compounding caused at least 73 reported compounding errors between 2001 and 2019. These errors led to more than 1,562 adverse events and at least 116 deaths. <https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2020/us-illnesses-and-deaths-associated-with-compounded-or-repackaged->

medications-2001-19 (U.S. Illnesses and Deaths Associated With Compounded or Repackaged Medications, 2001–19).

39. Lilly has seen problems first-hand for compounded tirzepatide. Lilly has discovered compounded drugs advertised as tirzepatide with safety, sterility, and efficacy problems. Some contain bacteria, high impurity levels, different colors (pink, instead of colorless), or a chemical structure different from the tirzepatide in Lilly’s FDA-approved medicines. In at least one instance, Lilly saw nothing more than sugar alcohol. Lilly also has received reports of patients experiencing significant adverse events after being injected with non-Lilly tirzepatide, including a patient who experienced a seizure and was admitted to the Intensive Care Unit and other patients who experienced severe allergic reactions. According to the FDA’s Adverse Events Reporting System (FAERS), to date, over 150 adverse events associated with compounded or so-called (but not actually) “generic” tirzepatide have been reported, including over 100 “serious cases” and at least 5 deaths.

40. Consequences from compounded drugs may be deadly. In October 2012, compounded drugs contaminated with a fungus were shipped throughout the country and later injected into patients’ spines and joints. After these contaminated products were injected into nearly 14,000 patients, more than 60 people died of fungal meningitis. *Id.* Regarding this outbreak, the FDA has written:

The 2012 fungal meningitis outbreak was not an isolated event. It was the most serious in a long history of serious adverse events associated with contaminated, super-potent, mislabeled, or otherwise poor quality compounded drugs. In addition, many serious adverse events linked to poor quality compounded drugs, including outbreaks of infections and deaths have occurred since then. And, because most compounders do not report adverse events to FDA, the agency may not be aware of adverse events associated with compounded drugs unless a health care provider submits an adverse event report regarding his or her patients or a state official notifies FDA.

<https://www.fda.gov/media/102493/download> (FDA Compounding Progress Report).

**WIDESPREAD SAFETY CONCERNS
ABOUT COMPOUNDED TIRZEPATIDE**

41. Regulators and law enforcement across the United States and abroad have recognized the safety concerns with compounded tirzepatide and other incretins. They have issued warnings, and in at least one instance, banned incretin compounding.

42. The FDA, for example, has consistently and repeatedly raised its concerns with compounding generally and compounded incretins more specifically.

<https://www.fda.gov/media/97347/download> (FDA prescription requirement compliance guidance for industry). The FDA specifically has targeted compounded tirzepatide as a threat to consumer safety. The Director of the FDA’s Office of Unapproved Drugs and Labeling Compliance has issued multiple warning letters to compounding pharmacies purportedly selling compounded tirzepatide products because they are not safe or effective.

<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024> (FDA warning letter re US Chem Labs);

<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synthetix-inc-dba-helix-chemical-supply-668918-02072024> (FDA warning letter re Synthetix Inc. DBA Helix Chemical Supply).

43. Across the country, at least nine state pharmacy boards, along with several state poison centers, have issued guidance and warnings regarding the risks to patients of compounded incretins. The Alabama Board of Pharmacy notified all licensed pharmacists and pharmacies that “even when compounding of [incretins] is allowable under [federal law], . . . the use of any non-pharmaceutical grade active pharmaceutical ingredient (API), or one not produced by an FDA-registered establishment, is prohibited.” <https://www.albme.gov/press-release/concerns-with-semaglutide-and-other-glp-1-receptor-agonists> (Alabama Board of Medical Examiners

press release). And the Maryland Poison Control Center warned that buying compounded incretins “online puts people at risk due to the medicine not being regulated and/or being sold from a source that is not licensed,” including because those compounded products “have not been evaluated for safety and effectiveness by the FDA.”

<https://blog.mdpoison.com/2024/03/semaglutide> (Blog of the Maryland Poison Center).

44. The issue of unsafe compounded drugs purporting to contain tirzepatide has also received international attention. Australia recently banned the development and sale of compounded anti-obesity medications because of “increasing community concern” and “increasing reports of patients coming to harm from” compounded incretin drugs. The ban—effective October 2024—targets compounded drugs that are “being misrepresented and sold as replica [] Mounjaro®.” <https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/protecting-australians-from-unsafe-compounding-of-replica-weight-loss-products> (Australia Minister for Health and Aged Care press release). As Mark Butler, Australia’s Minister for Health, said, “Australians should be able to have faith in the medications they use, including compounded medicines,” and the ban “will protect Australians from harm and save lives.” *Id.*

45. Doctors and patient groups recognize the problems with compounded incretins, and they are sharing their concerns, too. The Obesity Society, Obesity Action Coalition, and Obesity Medicine Association, for example, issued a joint statement warning that when people use incretin “alternatives, you may not be getting what you hoped for. You may also get something you did not want (other active substances have been found in some compounded versions).” <https://www.obesityaction.org/wp-content/uploads/GLP-1-Compounded->

Alternative-Statement_Final_Logos-1.pdf (joint statement from leading obesity expert organizations).

46. Lilly itself has issued multiple public warnings about compounded tirzepatide, including by publishing an open letter.

**DEFENDANT’S FALSE ADVERTISING AND
TRADEMARK INFRINGEMENT**

47. Lilly does not sell MOUNJARO[®] or ZEPBOUND[®] to Defendant for resale or redistribution. Nor has Lilly authorized Defendant to use the Lilly Marks in connection with any of Defendant’s offered goods or services. On information and belief, therefore, the Unapproved Compounded Drugs sold by Defendant are made by compounding pharmacies, which deliver them to Defendant for prescription, administration, or other dispensing to patients.


48. On information and belief, Defendant does not sell Lilly’s MOUNJARO[®] and ZEPBOUND[®] and has no association with Lilly. Yet Defendant boldly and falsely appropriates the Lilly Marks to market and sell Unapproved Compounded Drugs purporting to contain tirzepatide. These drugs are *not* MOUNJARO[®] or ZEPBOUND[®]. Rather, Defendant passes off Unapproved Compounded Drugs as the same as “Mounjaro” or as “generic Mounjaro.” Defendant’s unlawful use of the Lilly Marks can only be intended to deceptively lure in patients in pursuit of revenues and profits.

49. Because Defendant is not offering genuine MOUNJARO[®] or ZEPBOUND[®], Lilly has no control over the safety, quality, or effectiveness of the Unapproved Compounded Drugs sold by Defendant.

50. Defendant also passes off as “Mounjaro” or “generic Mounjaro” its own Unapproved Compounded Drugs for a use for which it is not approved or indicated, namely “weight loss.”

51. Examples of Defendant's trademark infringement and false advertising are shown below and are attached hereto as **Exhibit B**.

52. An example of Defendant's unauthorized use of the Lilly Marks, from an October 17, 2023 post to Defendant's Instagram page, is shown below.



53. As the image shows, Defendant promotes its Unapproved Compounded Drugs by first noting that its Unapproved Compounded Drugs contain the same active ingredient as in

MOUNJARO[®] and then switching to describing its product as “Sold as Mounjaro” and tagging the post #mounjaro as well.

54. Defendant interchanges “Tirzepatide” (the name for its Unapproved Compounded Drug) and “MOUNJARO[®]” (Lilly’s trademarked name for its FDA-approved medicine) on its website, too.

55. For example, as shown below, Defendant’s characterization of its products side effects (none of which have been scientifically proven) notes that “These are not all the possible side effects of Mounjaro.”

The most common side effects of Tirzepatide include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effects you might experience.

56. Defendant’s social media and website convey the unmistakable impression that Defendant is offering for sale a product that either is, has the same source as, or is the same as, Lilly’s MOUNJARO[®] and ZEPBOUND[®]. But Lilly is the only approved source of MOUNJARO[®] and ZEPBOUND[®] in the United States, and Lilly does not sell either medicine to Defendant for resale or redistribution.

57. Defendant first started using the Lilly Marks to advertise its Unapproved Compounded Drugs long after Lilly had adopted them. Defendant’s use can only have been intended to benefit from the goodwill Lilly generated around the Lilly Marks.

58. Defendant also falsely advertises its Unapproved Compounded Drugs on its website and social media by making statements that claim or imply that its Unapproved Compounded Drugs are FDA-approved and have been proven to achieve certain therapeutic outcomes. These statements rely on the FDA’s approval of *Lilly’s* medicines and clinical trials for *Lilly’s* medicines. These studies and approvals have no bearing on, and cannot substantiate

claims about, Defendant's Unapproved Compounded Drugs, which upon information and belief are sold without having undergone any clinical trials on safety and effectiveness.

59. For example, in the Instagram post shown above, Defendant cited to a "New Study Show[ing] Even More Promise for Tirzepatide Users." This study, however, was of *Lilly's* medicine and has no bearing on Defendant's Unapproved Compounded Drugs.

60. Additionally, in a video posted to Defendant's tirzepatide webpage, Defendant refers to its product at timestamp 0:09 as "generic MOUNJARO®." There is, however, *no such thing* as "generic MOUNJARO®."

61. In another section of Defendant's tirzepatide webpage, as shown below, Defendant advertises that: (1) "Tirzepatide is [] FDA approved to decrease blood sugar" and that "the active ingredient in Mounjaro has shown remarkable weight loss effects." "Tirzepatide," however, is *not* approved for weight loss or any other condition; Lilly's MOUNJARO® and ZEPBOUND®, medicines *containing* tirzepatide, are FDA approved for the indications described above. Additionally, Defendant notes that it offers an "exclusive combination of Tirzepatide, BPC-157, and B6"—a combination that has *never* been studied in clinical trials, is *not* FDA approved, and is *not* the non-existent "generic MOUNJARO®" that Defendant claims it to be. Rather, Defendant offers Unapproved Compounded Drugs.

FAQs:

— What is Tirzepatide?

Tirzepatide is a once weekly injection that is FDA approved to decrease blood sugar. Since 2022 the active ingredient in Mounjaro has shown remarkable weight loss effects and is on the fast-track designation for its review for the treatment of obesity. Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract.

62. Upon information and belief, these statements are false and/or misleading as to Defendant's Unapproved Compounded Drugs, which are *not* "generic MOUNJARO[®]," are *not* "FDA approved," were *not* subjected to clinical trials, and therefore are *not* "clinically proven" to achieve any results.

63. Defendant continues to use the Lilly Marks, including in advertising and promotion on its website and social media, to deceive patients who, upon information and belief, are seeking to buy but are in fact not buying genuine FDA-approved MOUNJARO[®] and/or ZEPBOUND[®] to treat their serious health conditions.

64. Defendant's prominent and misleading use of the Lilly Marks is likely to cause consumers to falsely believe that they are purchasing MOUNJARO[®] and/or ZEPBOUND[®], that Defendant is a source for Lilly's FDA-approved treatment options MOUNJARO[®] and/or ZEPBOUND[®], that Defendant's Unapproved Compound Drugs are as safe and effective as Lilly's FDA-approved treatment options MOUNJARO[®] and ZEPBOUND[®], and/or that Defendant's services are provided, licensed, sponsored, authorized, or approved by, or otherwise associated or affiliated with, Lilly.

65. Defendant's use of the Lilly Marks is without the permission, consent, or authorization of Lilly. Defendant has no right to use, and Defendant knows that it has no right to use, the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs or otherwise. Defendant's advertising and promotional materials are false and misleading where they suggest and/or state an association with Lilly's FDA-approved MOUNJARO[®] and ZEPBOUND[®], because no such association exists.

66. There is no need for Defendant to use the Lilly Marks to advertise or promote its Unapproved Compounded Drugs purporting to contain tirzepatide, other than to trade upon Lilly's reputation and to create confusion in the marketplace and/or mislead patients with serious health conditions regarding the origin, identity, or source of Defendant's Unapproved Compounded Drugs.

67. Defendant's unauthorized use of the Lilly Marks is intended—and likely—to cause confusion, to cause mistake, or to deceive, and infringes Lilly's established exclusive rights in the Lilly Marks.

68. Upon information and belief, unless enjoined by this Court, Defendant will continue to use the Lilly Marks and/or otherwise falsely advertise its Unapproved Compounded Drugs as associated with or being MOUNJARO[®] and ZEPBOUND[®], all in violation of Lilly's rights.

HARM TO THE PEOPLE OF OHIO AND LILLY

69. Lilly's FDA-approved MOUNJARO[®] and ZEPBOUND[®] medications have undergone extensive clinical trials and approval processes. But these clinical studies and FDA approvals only apply to genuine Lilly MOUNJARO[®] and ZEPBOUND[®] used as directed by a prescribing physician. The clinical trials and approval processes do not inform the safety, quality, or effectiveness of Defendant's Unapproved Compounded Drugs.

70. Defendant's unlawful, misleading business model may expose patients to the serious risks described above. Critically, because Defendant falsely advertises and, without Lilly's consent, uses the Lilly Marks in connection with its Unapproved Compounded Drugs, patients are unlikely to know the unique risks associated with Defendant's untested, unapproved drugs.

71. Defendant advertises itself as providing MOUNJARO[®] and ZEPBOUND[®] (or their supposed equivalents), when in reality Defendant provides untested Unapproved Compounded Drugs. Defendant's promotional tactics are *intended* to mislead patients into believing that Unapproved Compounded Drugs are backed by clinical trials and have been approved by the FDA, when no such studies have been conducted, and neither the FDA nor any other regulatory body has approved them. Patients who take Defendant's Unapproved Compounded Drugs and suffer harm will have had no forewarning.

72. Not only does this deceitful content expose the people of Ohio to serious health risks, but Defendant's unlawful tactics undermine the name, goodwill, and reputation that Lilly has invested heavily in developing. Moreover, Defendant's unfair methods allow it and its suppliers of Unapproved Compounded Drugs to unjustly profit from sales to patients looking for MOUNJARO[®] and ZEPBOUND[®].

FIRST CAUSE OF ACTION
Trademark Infringement
in Violation of 15 U.S.C. § 1114

73. Lilly repeats and realleges each and every allegation above as if fully set forth herein.

74. Lilly is the owner of all right, title, and interest in federal trademark registrations for the inherently distinctive Lilly Marks and has standing to maintain an action for trademark infringement under 15 U.S.C. § 1114.

75. Without Lilly's consent, Defendant has used and continues to use in commerce the Lilly Marks in connection with the offering, sale, and advertising of its Unapproved Compounded Drugs purporting to contain tirzepatide. Consumers who encounter Defendant's unauthorized use of the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs and related goods and services are likely to think that they are provided, licensed, sponsored, authorized, or approved by, or otherwise associated or affiliated with, Lilly.

76. Defendant's actions are likely to cause confusion, or to cause mistake, or to deceive, and thus constitute trademark infringement of the registered Lilly Marks, in violation of Section 32 of the Lanham Act, 15 U.S.C. § 1114.

77. Defendant had actual and/or constructive knowledge of Lilly's rights prior to its infringing use of the Lilly Marks. The actions of Defendant alleged above have at all times relevant to this action been willful.

78. As a direct and proximate result of the actions of Defendant alleged above, Lilly has been damaged and will continue to be damaged. Defendant's conduct, unless enjoined by the Court, will further impair the value of the Lilly Marks' name, reputation, and goodwill. This harm constitutes an injury for which Lilly has no adequate remedy at law.

79. This is an exceptional case under 15 U.S.C. § 1117.

80. Based on such conduct, Lilly is entitled to injunctive relief as well as monetary damages, and other remedies provided by Sections 1116, 1117, and 1118, including Defendant's profits, treble damages, reasonable attorneys' fees, costs, and prejudgment interest.

SECOND CAUSE OF ACTION
**Trademark Infringement, False Designation of Origin
and Unfair Competition in Violation of 15 U.S.C. § 1125**

81. Lilly repeats and realleges each and every allegation above as if fully set forth herein.

82. Lilly is the owner of all right, title, and interest in the inherently distinctive Lilly Marks and has standing to maintain an action for trademark infringement, false designation of origin, and unfair competition under 15 U.S.C. § 1125.

83. Without Lilly's consent, Defendant has used and continues to use in commerce the Lilly Marks in connection with the offering, sale, and advertising of its Unapproved Compounded Drugs purporting to contain tirzepatide. Consumers who encounter Defendant's unauthorized use of the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs and related goods and services are likely to think that they are provided, licensed, sponsored, authorized, or approved by, or otherwise associated or affiliated with, Lilly.

84. Defendant's actions are likely to cause confusion, or to cause mistake, or to deceive as to the origin, sponsorship, or approval of the products and services and commercial activities of Defendant, and thus constitute trademark infringement, false designation of origin, and unfair competition with respect to the Lilly Marks, in violation of Section 43(a)(1)(A) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(A).

85. Defendant had actual and/or constructive knowledge of Lilly's rights prior to its infringing use of the Lilly Marks. The actions of Defendant alleged above have at all times relevant to this action been willful.

86. As a direct and proximate result of the actions of Defendant alleged above, Lilly has been damaged and will continue to be damaged. Defendant's conduct, unless enjoined by the Court, will further impair the value of the Lilly Marks' name, reputation, and goodwill. This harm constitutes an injury for which Lilly has no adequate remedy at law.

87. This is an exceptional case under 15 U.S.C. § 1117.

88. Based on such conduct, Lilly is entitled to injunctive relief as well as monetary damages, and other remedies provided by Sections 1116, 1117, and 1118, including Defendant's profits, treble damages, reasonable attorneys' fees, costs, and prejudgment interest.

THIRD CAUSE OF ACTION
False and Misleading Advertising and Promotion
in Violation of 15 U.S.C. § 1125(a)(1)(B)

89. Lilly repeats and realleges each and every allegation above as if fully set forth herein.

90. Defendant's commercial advertising claims described herein are false and misleading in violation of Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).

91. Defendant has knowingly and willfully made material false and misleading statements in its commercial advertisements for its Unapproved Compounded Drugs, and these statements regarding the Unapproved Compounded Drugs' safety, quality, effectiveness, and regulatory status have influenced and are likely to continue to influence consumers' purchasing decisions.

92. Defendant's statements—including its various literally false claims—have the tendency to deceive a substantial segment of consumers, who have relied or likely will rely on Defendant's false statements in making their tirzepatide-based medicine purchase decisions.

93. Defendant has caused its false statements to enter interstate trade or commerce.

94. As a direct and proximate result of Defendant's false and deceptive campaign, Lilly is suffering immediate and continuing irreparable injury for which there is no adequate remedy at law.

95. As a direct and proximate result of Defendant's false and deceptive campaign, Lilly has suffered and will continue to suffer significant monetary damages and discernible competitive injury by the direct diversion of sales from Lilly to Defendant and Defendant's

suppliers and by a loss of goodwill associated with Lilly's MOUNJARO[®] and ZEPBOUND[®] and the Lilly Marks.

96. This is an exceptional case under 15 U.S.C. § 1117.

97. Lilly is entitled to injunctive relief as well as monetary damages, and other remedies provided by Sections 1116, 1117, and 1118, including Defendant's profits, treble damages, reasonable attorneys' fees, costs, and prejudgment interest.

FOURTH CAUSE OF ACTION
Deceptive Trade Practices
in Violation of Ohio Rev. Code § 4165.01 *et seq.*

98. Lilly repeats and realleges each and every allegation above as if fully set forth herein.

99. The above-described acts of Defendant constitute deceptive trade practices in violation of Ohio Rev. Code § 4165.01 *et seq.*

100. Among other things, Ohio Rev. Code § 4165.02 defines actions that constitute a "deceptive trade practice" as including, but not limited to, the following:

- (1) Passes off goods or services as those of another;
- (2) Causes likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of goods or services;
- (3) Causes likelihood of confusion or misunderstanding as to affiliation, connection, or association with, or certification by, another;

* * *

- (7) Represents that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have or that a person has a sponsorship, approval, status, affiliation, or connection that the person does not have;

* * *

- (9) Represents that goods or services are of a particular standard, quality, or grade, or that goods are of a particular style or model, if they are of another;

* * *

- (11) Advertises goods or services with intent not to sell them as advertised;

101. As set forth herein, Defendant's actions fit within the scope of Ohio Rev. Code § 4165.02.

102. Without Lilly's consent, Defendant has used and continues to use in commerce the Lilly Marks in connection with the offering, sale, and advertising of its Unapproved Compounded Drugs purporting to contain tirzepatide. Consumers who encounter Defendant's unauthorized use of the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs and related goods and services are likely to think that they are provided, licensed, sponsored, authorized, or approved by, or otherwise associated or affiliated with, Lilly.

103. Defendant's actions are likely to cause confusion, or to cause mistake, or to deceive the public and consumers as to the origin, sponsorship, or approval of the products and services and commercial activities of Defendant, and thus constitute deceptive trade practices with respect to the Lilly Marks, in violation of Ohio Rev. Code § 4165.01 et seq.

104. Defendant had actual and/or constructive knowledge of Lilly's rights prior to its infringing use of the Lilly Marks. The actions of Defendant alleged above have at all times relevant to this action been willful with the intent to deceive.

105. Defendant's actions additionally include deceptively relying on Lilly's clinical trials for Mounjaro[®] and ZEPBOUND[®] to advertise Defendant's Unapproved Compounded Drugs. These representations amount to false assurances of the safety, quality, and effectiveness of Defendant's Unapproved Compounded Drugs. Defendant's false and misleading misrepresentations and omissions were material because they involve information that would be important to consumers, and therefore, likely their use of, or conduct, regarding Defendant's Unapproved Compounded Drugs.

106. As a direct and proximate result of the actions of Defendant alleged above, Lilly has been damaged and will continue to be damaged. Defendant's conduct, unless enjoined by

the Court, will further impair the value of the Lilly Marks' name, reputation, and goodwill. This harm constitutes an injury for which Lilly has no adequate remedy at law.

107. Members of the public are also likely to suffer injury from the above-described acts of Defendant by purchasing a drug that they believe to be genuine Mounjaro[®] and ZEPBOUND[®], not an Unapproved Compounded Drug.

108. Under the principles of equity, Lilly is entitled to entry of preliminary and permanent injunctive relief. In addition, Lilly is entitled to attorneys' fees and costs.

FIFTH CAUSE OF ACTION
Trademark Infringement and Unfair Competition
in Violation of Ohio Common Law

109. Lilly repeats and realleges each and every allegation above as if fully set forth herein.

110. The above-described acts of Defendant constitute trademark infringement and unfair competition in violation of Ohio common law.

111. Without Lilly's consent, Defendant has used and continues to use in commerce the Lilly Marks to pass off its Unapproved Compounded Drugs purporting to contain tirzepatide as genuine MOUNJARO[®] and ZEPBOUND[®].

112. Defendant's unauthorized use of the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs and related goods and services is likely to cause confusion, or to cause mistake, or to deceive as to the origin, sponsorship, or approval of the products and services and commercial activities of Defendant.

113. Consumers who encounter Defendant's unauthorized use of the Lilly Marks in connection with Defendant's Unapproved Compounded Drugs and related goods and services are likely to think that they are provided, licensed, sponsored, authorized, or approved by, or otherwise associated or affiliated with, Lilly.

114. Defendant's actions thereby unfairly and wrongfully exploit and infringe Lilly's trademark, goodwill, and reputation.

115. As a direct and proximate result of Defendant's trademark infringement and unfair methods of competition, Lilly has suffered and will continue to suffer significant monetary damages and a loss of goodwill associated with Lilly's MOUNJARO[®] and ZEPBOUND[®] medicines and the Lilly Marks. Defendant therefore has unfairly profited from the actions alleged.

116. By reason of Defendant's acts, Lilly's remedy at law is not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Lilly is entitled to entry of preliminary and permanent injunctive relief in addition to monetary damages.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff Lilly prays that this Court enter judgment in its favor on each and every claim for relief set forth above and award it relief including, but not limited to, the following:

1. An Order declaring that Defendant:
 - a. Infringed the federally registered Lilly Marks, in violation of 15 U.S.C. § 1114(1);
 - b. Infringed the Lilly Marks and engaged in trademark infringement, false designation of origin, and unfair competition, in violation of 15 U.S.C. § 1125(a)(1)(A);
 - c. Engaged in false and misleading advertising and promotion, in violation of 15 U.S.C. § 1125(a)(1)(B);
 - d. Engaged in deceptive trade practices, false advertising, unfair competition, and trademark infringement in violation of Ohio Rev. Code § 4165.01 *et seq.* and Ohio common law;
 - e. That each of the above acts was willful and knowing.
2. An injunction preliminarily and then permanently enjoining and restraining Defendant and its officers, agents, servants, employees, and attorneys and all persons acting in concert or participation with any of them, from:
 - a. Using the Lilly Marks or any mark confusingly similar to them, in connection with the advertising, promoting, marketing, selling or offering for sale of any goods or services (including, but not limited to, Unapproved Compounded Drugs) or otherwise engaging in any activity that is likely to cause confusion, cause mistake, or deceive or

otherwise infringe any rights of Plaintiff Lilly in the Lilly Marks or any similar mark;

- b. Falsely stating or suggesting that Defendant's Unapproved Compounded Drugs are genuine or generic versions of MOUNJARO[®] or ZEPBOUND[®], that Defendant is associated or connected in any way with Plaintiff or its products, or that Defendant's Unapproved Compounded Drugs are approved by the FDA, have been the subject of clinical studies, or achieve certain therapeutic outcomes;
- c. Engaging in any unfair competition with Plaintiff Lilly; and
- d. Engaging in any deceptive or unfair acts.

3. An Order Requiring Defendant and its officers, agents, servants, employees, and attorneys and all persons acting in concert or participation with any of them, to engage in corrective advertising by informing consumers that Defendant is not and never has been authorized by, affiliated with, sponsored by, approved by, or related to Plaintiff Lilly or MOUNJARO[®] and ZEPBOUND[®], that Defendant's Unapproved Compounded Drugs are not MOUNJARO[®] or ZEPBOUND[®], that Defendant's Unapproved Compounded Drugs are not generic MOUNJARO[®] or generic ZEPBOUND[®], that Defendant's Unapproved Compounded Drugs have never been genuine or generic versions of MOUNJARO[®] and ZEPBOUND[®], and that Defendant's Unapproved Compounded Drugs are not and have never been approved or reviewed by the FDA or tested for safety, quality, or effectiveness in clinical trials.

4. An Order directing Defendant to file with this Court and serve on Lilly's attorneys, thirty (30) days after the date of entry of any injunction, a report in writing and under

oath setting forth in detail the manner and form in which they have complied with the Court's injunction.

5. An Order requiring Defendant to account for and pay to Lilly any and all profits arising from the foregoing acts of infringement, false designation of origin, false advertising, and deceptive trade practices.

6. An Order requiring Defendant to pay Lilly compensatory damages in an amount as yet undetermined caused by the foregoing acts of infringement, false designation of origin, false advertising, and unfair competition, and trebling such compensatory damages for payment to Lilly in accordance with 15 U.S.C. § 1117 and other applicable laws.

7. An Order for pre-judgment and post-judgment interest on all damages.

8. An Order requiring Defendant to pay Lilly all types of monetary remedies available under Ohio state law in amounts as of yet undetermined caused by the foregoing acts of infringement, false designation of origin, false advertising, and unfair competition.

9. An Order requiring Defendant to pay Lilly's costs and attorney's fees in this action pursuant to 15 U.S.C. § 1117, Ohio state law, and any other applicable provision of law.

10. Other relief as the Court may deem appropriate.

Dated: June 20, 2024

Respectfully submitted,
/s/ Matthew J. Cavanagh

Matthew J. Cavanagh (OH 0079522)
MCDONALD HOPKINS LLC
600 Superior Avenue, East, Ste. 2100
Cleveland, Ohio 44114
Telephone: (216) 348-5400
Facsimile: (216) 348-5474
mcavanagh@mcdonaldhopkins.com

Joshua L. Simmons (*pro hac vice* forthcoming)
Jeanna M. Wacker (*pro hac vice* forthcoming)
Ashley Ross (*pro hac vice* forthcoming)
Joshua C. Berlowitz (*pro hac vice* forthcoming)
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, New York 10022
Telephone: (212) 446-4800
Facsimile: (212) 446-4900
joshua.simmons@kirkland.com
jeanna.wacker@kirkland.com
ashley.ross@kirkland.com
josh.berlowitz@kirkland.com

Diana M. Watral (*pro hac vice* forthcoming)
James F. Hurst (*pro hac vice* forthcoming)
KIRKLAND & ELLIS LLP
333 West Wolf Point Plaza
Chicago, Illinois 60654
Telephone: (312) 862-2000
Facsimile: (312) 862-2200
diana.watral@kirkland.com
james.hurst@kirkland.com

Attorneys for Plaintiff
ELI LILLY AND COMPANY

JURY DEMAND

Lilly hereby demands a jury trial for all issues so triable.

/s/ Matthew J. Cavanagh

Matthew J. Cavanagh (OH 0079522)

Attorney for Plaintiff

ELI LILLY AND COMPANY

EXHIBIT A

United States of America

United States Patent and Trademark Office

MOUNJARO

Reg. No. 6,809,369

Registered Aug. 02, 2022

Int. Cl.: 5

Trademark

Principal Register

Eli Lilly and Company (INDIANA CORPORATION)
Lilly Corporate Center
Indianapolis, INDIANA 46285

CLASS 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes

FIRST USE 6-3-2022; IN COMMERCE 6-3-2022

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

SER. NO. 88-680,946, FILED 11-05-2019



Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.

United States of America
United States Patent and Trademark Office

MOUNJARO

Reg. No. 7,068,463

Registered May 30, 2023

Int. Cl.: 44

Service Mark

Principal Register

Eli Lilly and Company (INDIANA CORPORATION)
Lilly Corporate Center
Indianapolis, INDIANA 46285

CLASS 44: Medical information services in the field of diabetes

FIRST USE 6-7-2022; IN COMMERCE 6-7-2022

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO
ANY PARTICULAR FONT STYLE, SIZE OR COLOR

SER. NO. 97-468,410, FILED 06-21-2022

Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.

United States of America

United States Patent and Trademark Office

ZEPBOUND

Reg. No. 7,288,373

Registered Jan. 23, 2024

Int. Cl.: 5

Trademark

Principal Register

Eli Lilly and Company (INDIANA CORPORATION)
Lilly Corporate Center
Indianapolis, INDIANA 46285

CLASS 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of obesity

FIRST USE 11-30-2023; IN COMMERCE 11-30-2023

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

SER. NO. 97-362,818, FILED 04-14-2022

Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.

EXHIBIT B



Tirzepatide Injection



Welcome to Cleveland Health Group
HORMONE REPLACEMENT AND ANTI-AGING CENTER

Book Your Appointment Now
Request More Information

The Most Effective Weight Loss Medication Ever Available is NOW at Cleveland Health Group.

Tirzepatide Injection for Weight Loss

Tirzepatide, the active ingredient in FDA approved Mounjaro® and Zepbound™ is a once-weekly injection to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity. On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Tirzepatide works in multiple ways:

- Reduces how much food is eaten
- Stops the liver from making and releasing too much sugar
- Slows down how quickly food leaves the stomach
- The body releases insulin when blood sugar is high
- The body removes excess sugar from the blood

Cleveland Health Group's exclusive combination of Tirzepatide and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat. Studies show this action may occur in the brain.

Lifestyle modifications and calorie restriction will lead to overall better results. Benefits of weight loss are: improved comorbidities of obesity such as diabetes, high blood pressure, abnormal blood lipids and heart disease which can be seen with as little as a 5% weight loss.

The most common side effects of Tirzepatide include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effects you might experience.

Here at Cleveland Health Group we are always available to take your call and answer your commonly asked questions about the popular weight loss drugs Semaglutide and Tirzepatide. Here are some FAQs to help our patients learn more about these state-of-the-art treatments so you can make a well-informed decision.



FAQs:

- + What is Tirzepatide? ➤
- + What is Semaglutide? ➤
- + What is the difference between Tirzepatide and Semaglutide? ➤
- + Who are good candidates for Semaglutide or Tirzepatide? ➤
- + What are the benefits of Semaglutide or Tirzepatide treatments? ➤
- + How often will I need treatments? ➤
- + What are the side-effects of Semaglutide or Tirzepatide? ➤
- + How long does Semaglutide or Tirzepatide take to work? ➤

How much does Tirzepatide cost?

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option.

Pricing starts at \$75 per injection at our Independence location including follow-up consultations and weight loss monitoring. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

Call **216-927-9900** or visit clevelandhealthgroup.com to schedule your complimentary consultation.

Schedule a Consultation Today!

- + How much does Semaglutide or Tirzepatide cost? >
- + Can I get Semaglutide or Tirzepatide if I live out of state? >
- + Can I get Semaglutide or Tirzepatide if I live in Ohio, but not near the Independence office? >

Schedule An Appointment

Please provide the requested information and our Scheduling Coordinator will contact you as soon as possible to confirm your appointment time and date.

First name*	Last Name*
Email*	Phone*
Message/Questions	
<input type="checkbox"/> I agree to the Terms of Use*	
SUBMIT	

Get In Touch

✉ Email: clevelandhealthgroup@gmail.com

☎ Phone: (216) 927-9900 | Phone: (216) 927-9900

📍 Directions: 6571 Brecksville Rd., Independence, OH 44131



BBB Rating & Accreditation



Accredited Since: 5/27/2019
Years in Business: 5

Financing Options

At Cleveland Health Group, we are pleased to offer affordable financing options through CareCredit to cover your medical expenses. CareCredit makes it easier for people to get the care they want and need, right when they need it, without having to delay treatment or appointments.

HSA also accepted.



CLEVELAND HEALTH GROUP

WHAT IS TIRZEPATIDE?

- The active Ingredient In Mounjaro, Tirzepatide, Is a once a week Injection that Is FDA approved to decrease blood sugar.
- Our exclusive combination of Tirzepatide, and B6 helps with weight loss by decreasing food Intake and slowing down how fast food travels through your digestive tract.
- On average patients saw and astounding weight loss of over 20% of the Initial body weight.

CLEVELAND HEALTH GROUP

Cleveland Health Group
January 12 · Independence, OH · 🌐

WHAT IS TIRZEPATIDE?

The active Ingredient In Mounjaro, Tirzepatide, Is a once a week Injection that Is FDA approved to decrease blood sugar.

Call us for a consultation to see how Tirzepatide can benefit you!
— at Cleveland Health Group.

1

Like Comment Share

Write a comment...

CLEVELAND HEALTH GROUP

WHAT IS TIRZEPATIDE?

- The active Ingredient In Mounjaro, Tirzepatide, Is a once a week Injection that Is FDA approved to decrease blood sugar.
- Our exclusive combination of Tirzepatide, and B6 helps with weight loss by decreasing food Intake and slowing down how fast food travels through your digestive tract.
- On average patients saw and astounding weight loss of over 20% of the Initial body weight.

CLEVELAND HEALTH GROUP

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group WHAT IS TIRZEPATIDE?

The active Ingredient In Mounjaro, Tirzepatide. Is a once a week Injection that Is FDA approved to decrease blood sugar.

Call us for a consultation to see how Tirzepatide can benefit you!
216-927-9900
Edited · 20w

Liked by msnovember216 and others
January 12

Add a comment... Post

TIRZEPATIDE

Most Effective Weight Loss Medication That Has Ever Been Available!

- * Reduces Appetite & Hunger
- * One Injection, Once a Week
- * Lose at Least a Quarter of Initial Body Weight

CONTACT US NOW:
216-927-9900 **www.clevelandhealthgroup.com**

CLEVELAND HEALTH GROUP

cleveland_health_group • Follow
 Cleveland Health Group

cleveland_health_group New Study Shows Even More Promise for Tirzepatide Users.

The results confirm that the drug has the potential to be one of the most powerful medical treatments for obesity to date. The medicine in the diabetes drug Mounjaro helped people with obesity lose at least a quarter of their body weight, or about 60 pounds on average. This is combined with an intensive diet and exercise routine.

"We're doing a medical gastric bypass," said Dr. Caroline Apovian, who treats obesity at Brigham and Women's Hospital.

The injected drug, Tirzepatide, was approved in the U.S. in May 2022 to treat diabetes. Sold as Mounjaro, it has been used "off-label" to treat obesity, joining a frenzy of demand for diabetes and weight-loss medications including Ozempic and Wegovy.

Tirzepatide targets two hormones that kick in after people eat to regulate appetite and the feeling of fullness communicated between the gut and the brain.

Overall, nearly 29% of those taking the drug lost at least a quarter of their body weight, compared with just over 1% of those taking placebo.

#clevelandhealthgroup #weightloss #tirzepatide #mounjaro
 Edited · 32w

5 likes
 October 17, 2023

Add a comment... Post



Cleveland Health Group
November 22, 2023 · 🌐

The night before Thanksgiving is traditionally one of the largest party nights of the year. Are you ready?

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic #thanksgiving #friendsgiving See less



Search Facebook



Weight Loss Now! Tirzepatide and Semaglutide Find out which will be your weight loss super weapon!

www.clevelandhealthgroup.com



Cleveland Health Group

June 7, 2023 · Independence, OH · 🌐

Are you missing out on the hottest weight loss solution sweeping the nation?
Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option. Call 216-927-9900 or visit

CLEVELAND HEALTH GROUP

WEIGHT LOSS RESULTS

- ✓ Tirzepatide
- ✓ Semaglutide
- ✓ AOD-g604
- ✓ BioTE

YOU ARE #1

216-927-9900
www.clevelandhealthgroup.com

Cleveland Health Group
October 9, 2023 · 🌐

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom. Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide See less

Cleveland Health Group

clevelandhealthgroup.com

Closed now

Price Range - \$

Not yet rated (3 Reviews)

Photos

See all photos



Privacy · Consumer Health Privacy · Terms · Advertising · Ad Choices · Cookies · More · Meta © 2024

Write a comment...

Cleveland Health Group

January 18, 2023

The most effective weight loss medication available, is NOW at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity. On average patients saw an astounding weight-loss of over 20% of their initial body weight.

This is available to Ohio residents only.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation.

TIKTOK.COM

ClevelandHealthGroup on TikTok

Tirzepatide, the active ingredient in Mounjaro, will be available soon. #mounjaro #ozempic #ti...

CLEVELAND HEALTH GROUP

HEALTHY WEIGHT LOSS
NO CONTRACTS
NO MEMBERSHIPS
NO COUPONS

TIRZEPATIDE
SEMAGLUTIDE
AOD-9604
WHICH WILL WORK FOR YOU?

WWW.CLEVELANDHEALTHGROUP.COM 216-927-9900

Cleveland Health Group
September 26, 2023

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom. Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide See less

CLEVELAND HEALTH GROUP

LOSE THE WEIGHT

216-927-9900

TIRZEPATIDE
Decreases food intake & slows down how fast food travels through your digestive track. This helps you feel fuller longer & reduces how much you eat. On average patients saw a weight loss of over 20%

SEMAGLUTIDE
Lowers body weight by reducing appetite & hunger while curbing food cravings & altering food preferences. On average patients lost 15% of initial body weight.

Cleveland Health Group
March 15, 2023 · Independence, OH ·

The most effective weight loss medications on the market are available at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option. Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaqlutide See less

CLEVELAND HEALTH GROUP

WHAT ARE YOU WAITING FOR?

The most effective weight loss medication available.

Cleveland Health Group

July 18, 2023 · Independence, OH · 0

What are you waiting for?
Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.


On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.



Cleveland Health Group
January 25, 2023

Tirzepatide or Semaglutide? Two of the most effective weight loss medications available are NOW at Cleveland Health Group! But which is right for you?

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option. Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.
#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide See less

REAL WEIGHT LOSS

TWO OPTIONS

SEMAGLUTIDE | TIRZEPATIDE

CALL 216-927-9900
 WEB WWW.CLEVELANDHEALTHGROUP.COM
 6571 Brecksville Rd., Independence 44131

Cleveland Health Group
 November 19, 2023 · 🌐

The only thing that should be stuffed this Thanksgiving is the turkey 🦃

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic See less

2WAYS

TO LOSE WEIGHT



TIRZEPATIDE
Decreases food intake and slows down how fast food travels through your digestive track. This helps you feel fuller longer and reduces how much you eat.
On average patients saw a weight loss of over 20%

SEMAGLUTIDE
Lowers body weight by reducing appetite and hunger while curbing food cravings and altering food preferences.
On average patients lost 15% of initial body weight.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation.

Cleveland Health Group

January 18, 2023 · Independence, OH ·

Two of the most effective weight loss medications available are NOW at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option. Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

Call 216-927-990 or visit clevelandhealthgroup.com to schedule your complimentary consultation.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide See less

TIRZEPATIDE
Most Effective Weight Loss Medication That Has Ever Been Available!
Reduces Appetite & Hunger
One Injection, Once a Week
Lose Over 20% of Initial Body Weight

Contact Us Now:
216-927-9900 www.clevelandhealthgroup.com

CLEVELAND HEALTH GROUP

cleveland_health_group • Follow
 Cleveland Health Group

cleveland_health_group The most effective weight loss medication ever available is NOW at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity. On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Tirzepatide works in multiple ways:

- * Reduce how much food is eaten.
- * Stops the liver from making and releasing too much sugar.
- * Slows down how quickly food leaves the stomach.* The body removes excess sugar from the blood.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat. Studies show this action may occur in the brain.

Lifestyle modifications and calorie restriction will lead to overall

2 likes
 January 12, 2023

Add a comment... Post

WHAT ARE YOU WAITING FOR?

The most effective weight loss medication available.

Instagram

- Home
- Search
- Explore
- Reels
- Messages
- Notifications
- Create
- Profile
- Threads
- More

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group What are you waiting for?

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

Be the first to like this
May 24, 2023

Add a comment... Post

HAPPY THANKSGIVING

REAL WEIGHT LOSS

TIRZEPATIDE **CLEVELAND HEALTH GROUP** **SEMAGLUTIDE**

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group The night before Thanksgiving is traditionally one of the largest party nights of the year. Are you ready?

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic #thanksgiving #friendsgiving

27w

2 likes
November 22, 2023

Add a comment... [Post](#)



WHAT WE OFFER



WEIGHTLOSS

FDA Approved Semaglutide or Tirzepatide once a week injection can help with chronic weight management along with other benefits.



HORMONE REPLACEMENT THERAPY

The BioTE method of hormone replacement therapy consists of bioidentical pellets that are custom compounded based on your blood levels



PAIN MANAGEMENT

Many years of experience have confirmed that certain pathological alterations of tendons, ligaments, capsules, muscles and bones – in other words the root causes of your pain – can be eliminated systematically with ESWT.



ANTI-AGING

The fusion of ultrasound and radio frequency technologies represents a cutting-edge approach that provides a comprehensive and effective solution for facial rejuvenation.

cleveland_health_group • Follow
Cleveland Health Group

WHAT WE DO

The skilled medical professionals at Cleveland Health Group are dedicated to helping men and women in their quest for optimal health and overall well-being. We are consistently offering the latest in cutting edge technology and protocols to help treat hormonal imbalances, weight control, anti-aging and aesthetic techniques, and pain management.

Rediscover optimal health from within and transform your external vitality. Get on the path to wellness today! 🌟

📞 (216) 927-9900

We are now offering extended hours in 2024! See below for our full availability! 🌟

HOURS:
Monday 7am - 5pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 5pm
Saturday 9am - 1pm

#ClevelandHealthGroup #HealthyinCLE #clevelandweightloss #hormonehealth #ohioweightloss #clevelandantiaging #ohioantiaging #hormonereplacementtherapy #hormonereplacementtherapyclinic #weightlossclinic #weightlossclinicleveland #healthyinCLE #biote

18w

👍 🗨️ 📌

Liked by **msnovember216** and others
January 26

😊 Add a comment... Post

Instagram

- Home
- Search
- Explore
- Reels
- Messages
- Notifications
- Create
- Profile
- Threads
- More

CLEVELAND HEALTH GROUP

LOSE THE WEIGHT
216-927-9900

TIRZEPATIDE
Decreases food intake & slows down how fast food travels through your digestive track. This helps you feel fuller longer & reduces how much you eat. On average patients saw a weight loss of over 20%

SEMAGLUTIDE
Lowers body weight by reducing appetite & hunger while curbing food cravings & altering food preferences. On average patients lost 15% of initial body weight.

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group The most effective weight loss medications on the market are available at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of

2 likes
March 15, 2023

Add a comment... Post

REAL WEIGHT LOSS

JAW DROPPING RESULTS

LIFE OF THE PARTY

TIRZEPATIDE SEMAGLUTIDE AOD-9604

INBODY BIOTE LIPO MIC

CLEVELAND HEALTH GROUP

216-927-9900 WWW.CLEVELANDHEALTHGROUP.COM

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group The holiday party season is ON!
Get jaw dropping results NOW with Cleveland Health Group.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic

26w

4 likes
December 1, 2023

Add a comment... Post

CLEVELAND HEALTH GROUP

Weight Loss Now! Tirzepatide and Semaglutide
Find out which will be your weight loss super weapon!

www.clevelandhealthgroup.com

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group Are you missing out on the hottest weight loss solution sweeping the nation?

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your

2 likes
June 7, 2023

Add a comment... Post

CLEVELAND HEALTH GROUP

WEIGHT LOSS RESULTS

- ✓ Tirzepatide
- ✓ Semaglutide
- ✓ AOD-g604
- ✓ BioTE

YOU ARE #1

216-927-9900
www.clevelandhealthgroup.com

cleveland_health_group • Follow
Cleveland Health Group

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

2 likes
October 9, 2023

Add a comment... Post

LOSE WEIGHT LOOK GREAT AND FEEL HEALTHY



ASK ABOUT

**Tirzepatide,
Semaglutide, and
AOD-9604**

www.clevelandhealthgroup.com



Cleveland Health Group
June 5, 2023 · Independence, OH ·

Real Weight Loss!

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option.

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

CLEVELAND HEALTH GROUP

HEALTHY WEIGHT LOSS
NO CONTRACTS
NO MEMBERSHIPS
NO COUPONS

**TIRZEPATIDE
SEMAGLUTIDE
AOD-9604**

WHICH WILL WORK FOR YOU?

WWW.CLEVELANDHEALTHGROUP.COM 216-927-9900

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

These are the hottest weight loss medications on the market.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity. On average patients saw an astounding weight loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes. On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio

2 likes
September 26, 2023

Add a comment... Post

Instagram

- Home
- Search
- Explore
- Reels
- Messages
- Notifications
- Create
- Profile
- Threads
- More

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group Real Results for Real Life!

Just a few weeks in and Cleveland Health Group client Christy is already down 25 pounds!

So what are you waiting for? Make the call today and see if Tirzepatide or Semaglutide is right for you.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

7 likes
February 10, 2023

Add a comment... Post

REAL WEIGHT LOSS
TWO OPTIONS
SEMAGLUTIDE | TIRZEPATIDE

CALL 216-927-9900
WEB WWW.CLEVELANDHEALTHGROUP.COM
6571 Brecksville Rd., Independence 44131

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group The only thing that should be stuffed this Thanksgiving is the turkey 🍗❤️

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic

27w

3 likes
November 19, 2023

Add a comment... [Post](#)

Instagram

Home Search Explore Reels Messages Notifications Create Profile Threads More

CLEVELAND HEALTH GROUP

TIRZEPATIDE OR SEMAGLUTIDE

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group Tirzepatide or Semaglutide? Two of the most effective weight loss medications available are NOW at Cleveland Health Group! But which is right for you?

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of

1 like
January 25, 2023

Add a comment... **Post**

LOSE WEIGHT
LOOK GREAT AND FEEL HEALTHY

CLEVELAND HEALTH GROUP

ASK ABOUT
Tirzepatide, Semaglutide, and AOD-9604

www.clevelandhealthgroup.com

cleveland_health_group • Follow
 Cleveland Health Group

cleveland_health_group Real Weight Loss!

Join the hundreds of Cleveland Health Group satisfied customers who have already discovered the benefits of Tirzepatide or Semaglutide.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

1 like
 June 5, 2023

Add a comment... Post



Cleveland Health Group
 February 21, 2023 · Independence, OH · 🌐

Celebrate Today... 🎉 Then call Cleveland Health Group and see if Tirzepatide or Semaglutide is right for you!

Two of the most effective weight loss medications available are NOW at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Just one injection, once a week is all it takes to begin your journey to weight loss freedom.

Cleveland Health Group offers two convenient choices for Ohio residents to get in on this revolutionary weight loss option. Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

Instagram

Home Search Explore Reels Messages Notifications Create Profile Threads More

FAT TUESDAY

CLEVELAND HEALTH GROUP

ENJOY TODAY!

THEN CALL CLEVELAND HEALTH GROUP AND SEE IF TIRZEPATIDE OR SEMALUTIDE IS RIGHT FOR YOU!

cleveland_health_group • Follow
Cleveland Health Group

cleveland_health_group Celebrate Today... 🎉 Then call Cleveland Health Group and see if Tirzepatide or Semaglutide is right for you!

Two of the most effective weight loss medications available are NOW at Cleveland Health Group!

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects, and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight-loss of over 20% of their initial body weight.

Cleveland Health Group's exclusive combination of Tirzepatide, BPC-157, and B6 helps with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat.

FDA approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

1 like
February 21, 2023

Add a comment... Post



BLACK FRIDAY

Cleveland Health Group
November 24, 2023 · 🌐

This Black Friday you shopped till you dropped. Now let Cleveland Health Group help you drop something else.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.


This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic #blackfriday See less



REAL WEIGHT LOSS

JAW DROPPING RESULTS

LIFE OF THE PARTY

**TIRZEPATIDE
SEMAGLUTIDE
AOD-9604**

**INBODY
BIOTE
LIPO MIC**

CLEVELAND HEALTH GROUP

216-927-9900 WWW.CLEVELANDHEALTHGROUP.COM

Cleveland Health Group
December 1, 2023 · 🌐

The holiday party season is ON!

Get jaw dropping results NOW with Cleveland Health Group.

The active ingredient in Mounjaro, Tirzepatide, is a once-weekly injection that is FDA-approved to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity.

On average patients saw an astounding weight loss of over 20% of their initial body weight.

FDA-approved Semaglutide lowers body weight by reducing appetite and hunger while also curbing food cravings and altering food preferences.

This exclusive compound for Cleveland Health Group is similar to a natural hormone in your body that causes insulin release in response to high blood sugar and decreases the amount of sugar your liver makes.

On average Semaglutide patients lost 15% of their initial body weight!

Call 216-927-9900 or visit clevelandhealthgroup.com to schedule your complimentary in-office consultation. You can also opt for a virtual consultation to see if treatment can be done in the comfort of your own home.

This is available to Ohio residents only.

#clevelandhealthgroup #tirzepatide #weightloss #mounjaro #semaglutide #ozempic See less

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____.

I personally served the summons on the individual at *(place)* _____
_____ on *(date)* _____; or

I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____, and mailed a copy to the individual's last known address; or

I served the summons on *(name of individual)* _____, who is
designated by law to accept service of process on behalf of *(name of organization)* _____
_____ on *(date)* _____; or

I returned the summons unexecuted because _____; or

Other *(specify)*: _____.

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____.

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc: